Primed Monocyte Program

Our primed monocytes are engineered myeloid cells  that stimulate an immune response to cancer.

We are advancing our glioblastoma program to clinical stage in partnership with Duke University after showing potent anti-tumor activity in animal cancer models.

Cell Therapy Programs

Using a harmonized, one-day manufacturing process, we are moving into the clinic with our ATAK  monocytes.  These myeloid cells are engineered with a novel CAR design that triggers tumor-specific phagocytosis and secretion of pro-inflammatory cytokines, resulting in a hot tumor microenvironment and causing tumor cell death.  In addition, ATAK monocytes sustain the ability to cross-present antigens, generating a durable anti-tumor response by cytotoxic T cells.

MT-101 is being developed for the treatment of relapsed and refractory CD5-expressing T cell lymphomas. Refractory PTCL is a lethal disease with limited treatment options, that until now has not benefited from innovations in cell therapy.

​

In vitro and in vivo studies show MT-101 demonstrated meaningful anti-tumor activity. Treatment in these models has been associated with potent phagocytosis responses, the production of inflammatory mediators and delays in tumor progression.
 

MT-102 is being developed for individuals with HER2 expressing cancers. In vivo studies show MT-102 has eradicated HER2+ tumors.

MT-103 targets tumors with TROP2 antigen.